Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade.

The authors showed a trend toward lower baseline Tregs and M-MDSC levels in non-relapsing patients as compared with relapsing ones, thus suggesting the negative impact of these circulating populations on the clinical outcome, without clearly distinguishing their predictive vs. prognostic value ( 51 ).

also in 53,322 other papers

The same authors observed that these signatures behaved similarly in metastatic melanoma patients treated with Nivolumab [analyzed in ( 92 )], although the differences between responders and non-responders did not reach statistical significance ( 93 ).

also in 111,027 other papers